Image source: The Motley Fool.
Fate Therapeutics Inc (FATE -5.02%)
Q1Â 2020 Earnings Call
May 11, 2020, 5:00 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Welcome to the Fate Therapeutics First Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Fate's website at fatetherapeutics.com As a reminder, today's call is being recorded.
I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics.
Scott Wolchko -- President & Chief Executive Officer
Thank you. Good afternoon, and thanks everyone for joining us for the Fate Therapeutics first quarter 2020 financial results call. Shortly after 4:00 p.m. Eastern Time today, we issued a press release with these results, which can be found on the investors and media section of our website under Press Releases. In addition, our Form 10-Q for the quarter ended March 31, 2020, was filed shortly thereafter and can be found on the Investors and Media section of our website under Financial Information.
Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Please see the forward-looking statement disclaimer on the Company's earnings press release issued after the market closed today as well as the risk factors in the Company's SEC filings included in our Form 10-Q for the quarter ended March 31, 2020, that was filed with the SEC today. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, as facts and circumstances underlying these forward-looking statements may change. Except as required by law, Fate Therapeutics disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances.
Joining me on today's call are Dr. Dan Shoemaker, our Chief Scientific Officer; Dr. Bob Valamehr, our Chief Development Officer; and Dr. Wayne Chu, our Senior Vice President of Clinical Development. Today, I will comment on the impact of the COVID-19 pandemic on our business, highlight key milestones we achieved during the past several months and discuss the transformative collaboration we recently entered into with Janssen.
The global COVID-19 pandemic has significantly impacted our daily lives, and we have been compelled to change our day-to-day operations to confront with these unprecedented times. We have taken numerous measures to protect the health and safety of our employees, their families, and the extended community, while continuing to operate our business.
Shortly after the JP Morgan conference, we reassessed our preparedness for a potential pandemic and began implementing changes to our operations. We confirm that our master iPSC lines and our manufactured clinical products were inventoried in redundant locations, and we stocked clinical sites with our clinical products to enable off-the-shelf administration to patients. We also worked with our suppliers to accelerate the sourcing of key materials to support the conduct of our planned in-house GMP manufacturing campaigns. We implemented a work-from-home policy and restricted on-site personnel to those conducting essential laboratory and manufacturing activities. We worked closely with our clinical trial sites and investigators to promote the safety and continued care of study participants, implemented remote site activation and patient monitoring and preserved data integrity.
We believe we have established operational capabilities, including full control of GMP manufacture that will allow us to operate with resolve and advance our business objectives. The commitment, resourcefulness, and resilience of our employees have carried us through these challenging weeks. We have been disrupted by the COVID-19, though, as the cadence of new clinical trial site initiation and patient enrollment has been slowed. While we remain committed to our clinical programs and development plans, these disruptions have introduced some uncertainty with respect to our projected time lines for enrollment and data readouts across our clinical trials. Nevertheless, we have maintained significant business momentum across our three clinical programs, all of which have continued to enroll patients. For each of our programs, we have manufactured hundreds of cryopreserved infusion-ready doses, which have been tested, released, and stored in inventory and are immediately available for use in our clinical studies.
With respect to our FT500 program, we have now treated three patients with FT500 at the 300-million cell dose level in combination with checkpoint inhibitor therapy and successfully completed enrollment in the dose escalation stage of the FT500 Phase 1 clinical trial in advanced solid tumors. We believe this is a significant clinical milestone as our FT500 Phase 1 study is the first ever clinical trial in the United States of an IPS-derived cell product. Additionally, it is one of the first ever clinical trials of a cell therapy to evaluate a novel multi-dose treatment course, consisting of outpatient lympho-conditioning followed by three once-weekly doses of FT500 over up to two 30-day treatment cycles.
I'm pleased to report that consistent with our prior clinical observations in the dose escalation stage of the FT500 Phase 1 study, there were no dose-limiting toxicities, no FT500-related Grade 3 or greater adverse events or serious adverse events, and no incidence of cytokine release syndrome, neurotoxicity, graft-versus-host disease reported by investigators in these three patients. Enrollment in the dose expansion stage of the FT500 Phase 1 study is proceeding at three clinical sites in patients with non-small cell lung cancer, where up to 40% of patients with resistance to checkpoint inhibitor therapy, exhibit partial or complete loss of MHC Class 1 expression, making these cancers highly susceptible to NK cell recognition and killing. We expect to treat up to 15 patients in the outpatient setting in the dose expansion stage, administering three once-weekly doses of FT500 at 300-million cells per dose over up to two 30-day cycles, along with IL-2 cytokine support and with the checkpoint inhibitor on which the patient failed or progressed.
FT516 is the second program emerging from our iPSC product platform and the first engineered IPS-derived cell therapy in the world to undergo clinical investigation. We continue to conduct the dose escalation stage of the FT516 Phase 1 clinical trial as a monotherapy for AML and in combination with rituximab for advanced B-cell lymphoma. We have successfully activated two additional sites for a total of three active sites, and we are currently working with two additional sites on remote activation. In addition, we successfully expanded the clinical scope of our FT516 program to advanced solid tumors. In January, the FDA allowed our second IND application for FT516, enabling clinical investigation in combination with PD-L1, PD-1 and EGFR and HER2-targeted monoclonal antibody therapies across a broad range of solid tumors. We intend to initially evaluate FT516 in combination with avelumab, an ADCC competent anti-PD-L1 immune checkpoint inhibitor in patients with advanced solid tumors who are refractory to or have relapsed following at least one line of anti-PD-L1 therapy. We expect first patient enrollment in combination with avelumab in the coming months.
With respect to our FT596 program, we treated the first patient in the dose escalation stage of the FT596 Phase 1 clinical trial for advanced B-cell malignancies and chronic lymphocytic leukemia. We are particularly excited about this clinical milestone. FT596 is the first ever cellular immunotherapy engineered with 3 active anti-tumor components to be evaluated in patients and is uniquely designed to target multiple tumor-associated antigens expressed on cancerous B cells for best-in-class potential. In addition to a proprietary CAR targeting CD19, FT596 expresses our novel, high affinity, non-cleavable CD16 Fc receptor, enabling multiple antigen targeting of CD19 and additional tumor associated antigens, such as CD20. FT596 also expresses a novel IL-15 receptor fusion, a potent cytokine complex that promotes survival, proliferation and transactivation of NK cells and CD8 T cells without the need for systemic cytokine support. One site is currently active, and we are currently working with three additional sites on remote activation.
In addition, I'm also pleased to announce that we have successfully expanded the clinical scope of our FT596 program as the FDA allowed a second IND application for FT596. Sponsored by investigators from the Masonic Cancer Center University of Minnesota, this new Phase 1 clinical study is intended to assess the potential of FT596 to prevent relapse in patients undergoing autologous hematopoietic stealth transplant for the treatment of non-Hodgkin lymphoma. The clinical trial is expected to enroll up to 18 patients considered high-risk for early relapse based on failure to achieve complete or partial remission on or relapse within 12 months of prior therapy. Up to three dose levels of FT596 will be administered in combination with rituximab 30 days following transplant.
We also continue to be excited about our rate of preclinical innovation, including our ability to add on additional engineered features and functionality, rapidly build next-generation product candidates and advance our pipeline of engineered IPS-derived NK cell product candidates into clinical development. I'm pleased to announce that we have recently submitted an IND application to the FDA for FT538, the first CRISPR-edited IPS-derived cell therapy. FT538 is derived from a clonal iPSC line engineered with hnCD16 and our IL-15 receptor fusion and edited for elimination of CD38 expression to mitigate anti-CD38, antibody-mediated fracture side. We intend to clinically investigate FT538 in combination with anti-CD38 monoclonal antibody therapy for the treatment of multiple myeloma.
In addition to FT538 as a clinical candidate, we believe the clonal master engineered iPSC line for FT538 may serve as a foundational cellular backbone for the building of future IPS-derived NK cell product candidates. For example, at this week's American Society of Gene and Cell Therapy Virtual Annual Meeting, we will highlight the creation of a master engineered iPSC line for FT576, our off-the-shelf IPS-derived CAR BCMA NK cell product candidate, using an existing master engineered iPSC line from the FT538 program as starting material. Similarly, at ASGCT, we will also present preclinical data for our recently announced CAR MICA, MICB program, targeting pan-tumor-associated stress proteins where the initial product candidate forms have been developed using existing master engineered iPSC line from the FT538 program.
As many of you know, about five years ago, when we set out on this journey to bring IPS-derived cell-based cancer immunotherapy to patients, our mission included both NK cells and T cells as the delivery of both cell types may ultimately play a critical role in curing cancer. We formed a foundational collaboration in 2016 with Memorial Sloan Kettering, led by Dr. Michel Sadelain, to guide our path in developing off-the-shelf IPS-derived CAR-T cell therapy. Over the years, we've followed the science and the clinical learnings emerging from the autologous CAR-T cell field and continued to innovate to include state-of-the-art features and functionality in our IPS-derived CAR-T cell programs. We pioneered the creation of a clonal master iPSC line engineered with a CAR inserted into the TRAC locus to regulate CAR expression, optimize cytotoxic activity and eliminate T cell receptor expression for mitigation of graft-versus-host disease risk. We refined our differentiation protocol with the goal of making potent alpha-beta T cells that closely match their naturally occurring counterparts. And we raised our IPS-derived CAR-T cell product candidates against primary CAR-T cells in the most stringent preclinical models under our collaboration with the founder of CAR-T cell therapy.
I'm pleased to announce that we remain on track to submit our IND application to the FDA in the second quarter for FT819, the world's first off-the-shelf IPS-derived CAR-T cell therapy. FT819 is derived from a clonal master iPSC line engineered with a novel 1XX CAR targeting CD19 inserted into the TRAC locus and edited for elimination of TCR expression. We continue to strive to bring FT819 to the first patient in 2020.
Finally, I'd like to make a few comments about our newly formed collaboration with Janssen. The partnership is transformative for us. And I believe it significantly increases our ability to invest in innovation, build commercial-scale iPSC manufacturing operations, bring best-in-class IPS-derived cell-based cancer immunotherapies to patients and deliver value to shareholders. The collaboration brings together Janssen's scientific leadership and deep domain expertise in oncology and our industry-leading iPSC product platform. Our mutual objective is to research, develop and commercialize novel off-the-shelf IPS-derived CAR NK and CAR-T cell products.
With respect to the collaboration scope, the collaboration is antigen targeted-based and includes both CAR NK and CAR-T cell candidates directed to up to four tumor-associated antigens. The binding domains directed to the four antigen targets are proprietary to and are being contributed by Janssen for construction of the CAR constructs. The cancers we are seeking to treat include both hematologic malignancies and solid tumors. Note that this is a deep collaboration in that it is not limited to a specific number of collaboration candidates. In fact, we can continue to innovate and develop next-generation collaboration candidates together against those four specific antigen targets.
Under the collaboration, we will drive and conduct innovation, preclinical development, and conduct IND-enabling activities for each IPS-derived CAR NK and CAR-T cell collaboration candidate. Importantly, all these activities are entirely funded by Janssen. And we will receive full funding for all innovation, preclinical development and the IND-enabling activities that we perform under the collaboration.
Upon the completion of activities sufficient to allow for submission of an IND, Janssen will have the right to exercise an exclusive option and obtain an exclusive license for the clinical development and commercialization of the collaboration candidate. Janssen will be solely responsible for worldwide clinical development and commercialization, and we will be primarily responsible for the manufacture at Janssen's cost of the collaboration candidate. For each collaboration candidate upon Janssen's attainment of clinical proof of concept, we have the right to elect to co-commercialize and share equally in the profits and losses in the United States, subject to sharing in certain development costs.
I'd like to emphasize that the collaboration candidates under the Janssen collaboration do not include any product candidates that are currently under clinical or preclinical development by us or otherwise part of our current product pipeline. We will continue to independently innovate and exploit our deep pipeline of wholly owned product candidates.
With respect to the collaboration economics, we received $100 million in April, of which $50 million was an upfront cash payment and $50 million was in the form of an equity investment at $31 per share. For the first antigen target, we are eligible to receive up to $898 million upon the achievement of specified development, regulatory and sales milestones for the first collaboration candidate and up to $460 million of milestone payments for each additional collaboration candidate. For each of the second, third, and fourth antigen targets, we are eligible to receive up to $706 million in proprietary -- in milestone payments for each of the first collaboration candidates and up to $340 million in milestone payments for each additional collaboration candidate.
In total, assuming only one collaboration candidate across each of the four antigen targets, we are eligible to receive payments of up to $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones. In the event we elect to co-commercialize a particular collaboration candidate, with the benefit of sharing equally in the profits and losses in the United States, these milestone payments are subject to reduction. In addition, we are eligible to receive double-digit royalties ranging up to the mid-teens on net sales of collaboration products that are commercialized by Janssen.
With respect to the collaboration's strategic value, I would highlight several key points. First, we have partnered with one of the strongest oncology teams in the entire industry, one with outstanding scientific, clinical development and commercialization expertise. We will be building collaboration candidates using proprietary binding domains identified and optimized by Janssen, creating the opportunity to develop highly differentiated products.
Second, Janssen has committed substantial dollars to the collaboration's work plan. And we will be receiving significant annual research and development payments to drive innovation, including for the research and development of next-generation features and functionality and for the scaling of our GMP manufacturing processes to support commercial-scale operations. Importantly, we retained rights to this innovation for use across our iPSC product platform. Furthermore, the collaboration represents an opportunity for us to leverage our industry-leading iPSC product platform and expand our product pipeline. We have not encumbered our existing product pipeline in any way whatsoever. For each collaboration candidate, we retained significant economic interest with the rights to opt in to co-commercialization and equal share of profits and losses in the U.S.
Lastly, I would highlight that we retained responsibility for the manufacture of collaboration products. Under the collaboration, we have formed a joint manufacturing committee where Janssen can provide advice and support for our activities in building and scaling a world-class cell therapy manufacturing operation.
I would like to thank the Janssen oncology team. These are uncertain times, and we're all facing new challenges during this COVID-19 pandemic. Janssen was unwavering in their commitment to this partnership. And I'm really appreciative and sincerely grateful for the significant time and effort that Janssen dedicated to finalizing this collaboration in the midst of the pandemic and at the trust that the Janssen team has placed in our team. I'm really excited to lead Fate Therapeutics as we begin this transformative collaboration together and dedicate ourselves to build novel off-the-shelf CAR NK and CAR-T cell cancer immunotherapies and bring life-changing medicines to patients.
Turning to our financial results. Revenue was $2.5 million for the first quarter of 2020 compared to $2.6 million for the same period last year. Revenue in the current quarter was derived from the Company's IPS-derived CAR-T cell collaboration with Ono Pharmaceutical. Research and development expenses for the first quarter of 2020 were $29.3 million compared to $17.7 million for the same period last year. The increase in our R&D expenses was attributable primarily to an increase in employee compensation, including share-based compensation, and expenses associated with the clinical development and manufacture of our product candidates, the conduct of research activities, including under our collaboration with Ono, and the facility lease for our new corporate headquarters.
General and administrative expenses for the first quarter of 2020 were $7.7 million compared to $5.4 million for the same period last year. The increase in our G&A expenses was attributable primarily to an increase in employee compensation, including share-based compensation and in legal and accounting fees. Total operating expenses for the first quarter of 2020 were $30.1 million, net of non-cash share-based compensation expense of $6.9 million.
The Company ended the first quarter of 2020 with $219 million of cash, cash equivalents and investments, which excludes $100 million received in April in connection with the Janssen collaboration. Common stock outstanding was 76 million shares and preferred convertible stock outstanding was 2.8 million shares, each of which is convertible into five shares of common stock under certain conditions. Common stock outstanding excludes the issuance of 1.6 million shares in April in connection with the Janssen collaboration.
The global pandemic has shaken all our lives, and many of us are experiencing first-time challenges and significant instability. I want to thank our employees for their passion, commitment, and resiliency. I'm proud that we have demonstrated our ability to act swiftly to changing times and remained unwavering in our commitment to bring our pipeline of engineered IPS-derived NK cells and T-cell cancer immunotherapies to patients during these unprecedented times.
I sincerely hope that all of you and your family members are well and staying safe. And I'd now like to open up the call to questions. Thank you.
Questions and Answers:
Operator
[Operator Instructions] Your first question comes from the line of Ted Tenthoff with Piper Sandler.
Ted Tenthoff -- Piper Sandler -- Analyst
Great. Thank you, guys. Congrats on all of the update across the pipeline, it's really exciting. Trying to get a sense for sort of where you see the applicability for 819 vis-a-vis the other products in development and out there currently. Really excited to see that one advance into the clinic and do think we would most likely get data sometime next year. But just want to get a little bit more color on 819. Thanks.
Scott Wolchko -- President & Chief Executive Officer
Sure. Wayne is currently located in San Francisco. Wayne, do you want to answer that -- take that question from Ted?
Yu-Waye Chu -- Senior Vice President, Clinical Development
Sure. So yes, we're very excited about FT819 entering the clinic. And I think it raises some very intriguing development questions and possibilities given the fact that we also have a product in FT596 where, based on what we know, we should also expect to see activity. And I think that the challenge from a clinical development perspective is finding indications that are most appropriate for the risk benefit profile of each of the products as we gain clinical data in our Phase 1 studies. And so I think that the answer to your question will largely be dictated by what we see in terms of efficacy and, more importantly, safety and tolerability because that will then define what are the most appropriate indications within B-cell leukemia and lymphomas in which to more fully develop these products.
Ted Tenthoff -- Piper Sandler -- Analyst
Great. Thank you very much.
Operator
Our next question comes from the line of Robyn Karnauskas with SunTrust Robinson.
Robyn Karnauskas -- SunTrust Robinson -- Analyst
Hi, guys. Thanks for taking the question. Q1 [Phonetic], so first of all, just when COVID happened, I don't know what that data point you want to define as were like trials sort of getting impacted, can you give us any sense of where you were in the time frame of 516 and 510 or FT500 enrollment? Just how many patients were flowing through, just so we have a sense of when the trial might have gotten disrupted? And were there any skip visits?
And then secondly, on the deal, congratulations on the deal, how are you thinking about future deals? And does this agreement have anything that would prevent you from doing them? Thank you.
Scott Wolchko -- President & Chief Executive Officer
Sure. I'll do those in reverse order. So there's nothing in the Janssen deal that prevents us from doing future deals other than we are mutually exclusive with Janssen on the four antigen targets. So those four specific antigen targets -- which are named, to be clear, we're working exclusively with Janssen on those four targets.
So obviously, if you think of the space of cancer immunotherapy, there are countless targets that you could potentially pursue and more emerging each and every day. And so yes, we absolutely have the opportunity to continue to do partnerships as we think about continuing to build our pipeline and leverage our platform. I think one of the exciting things that I mentioned, for instance, on this call, is that we are continuing to evolve our pipeline and our platform where we are creating multiplexed engineered product candidates. For instance, FT538 already has three engineered pieces of functionality in that cell product. We can use that now as a backbone essentially to create new product candidates, starting with that as the starting material.
So I think our ability to do -- develop highly multiplexed engineered product candidates is really exciting and is one of the things that we think, and I think partners think is very attractive about our platform as we think about how to, for instance, attack solid tumors, as an example, where I think it's going to take potentially highly engineered and edited solutions.
With respect to where we were on the trials, I agree, you can sort of debate when COVID hit. But we were in the midst -- with respect to FT500, we were in the midst of finishing the 300-million cell dose in the dose expansion -- or sorry, dose escalation stage, which we successfully completed. And to my knowledge, there were not any missed visits in completing dose escalation at 300 million cells per dose. And so I talked about the results on the call, obviously, we're super excited, continue to see really strong safety and tolerability, including going out into the second cycle where patients had received all six doses.
With respect to FT516, it's early. I mean, we treated the first patients in dose escalation, I think, in late October. And so we were just working our way early through dose escalation in the FT516 program.
Yu-Waye Chu -- Senior Vice President, Clinical Development
I would also just add that, as Scott mentioned, we were in the midst of dose escalation in all of our active trials when the COVID-19 situation became such that there were rules at the institutional level to restrict patients coming on to Phase 1 trial. And so we've been monitoring the institutional guidelines very closely and have been in very constant communication with investigators to ensure that patients who are on the trials are being monitored appropriately. And for the most part, despite the COVID-19 situation, patients are still adhering to their schedules with respect to monitoring even to the point of still continuing to come into clinic to have physical exams and lab draws and things like that. But cognizant of the impact of COVID-19, we have worked actively with clinical sites to ensure the possibility of remote monitoring and other contingencies in cases where patients are unable to come to the clinic.
Operator
Your next question comes from the line of Jim Birchenough with Wells Fargo.
Jim Birchenough -- Wells Fargo -- Analyst
Hi, guys. Congrats on all the progress, a lot to cover. So couple of questions. I guess, number one, could you just talk about how your platform allows you to be opportunistic as sites reopen for patient dosing? Have you been able to ship all those doses that you mentioned to different sites? And maybe compare how you're able to be opportunistic as sites open versus other cell therapies.
Scott Wolchko -- President & Chief Executive Officer
Yeah. I think it's one of the unique advantages that we have. Obviously, with an IPS cell platform, you have the ability for -- to truly have an off-the-shelf product paradigm much closer to more like a monoclonal antibody therapy. So yes, we absolutely -- we have hundreds of manufacturer doses that are already cryopreserved. We have redundancies with respect to where those doses are housed. Certainly, some of the doses are housed at our distributor. We have a distributor. Other -- but we absolutely have stocked our clinical sites with doses. And so our clinical sites have doses stored on site. And obviously, we're also promoting an outpatient paradigm for being able to treat patients. So, as we come out and try and emerge from this COVID-19 pandemic, I do think we're in a really unique situation where we can potentially accelerate out of it in a much, much quicker fashion than we might otherwise face if we were doing traditional cell-based therapy where you were requiring sourcing, patient or donor cells for every batch to batch manufacturing run.
Jim Birchenough -- Wells Fargo -- Analyst
And then maybe just, Scott, following up on the Janssen deal, and congrats on that deal, for the individual targets that get selected, is there anything that prevents Janssen from pursuing ADCs or bispecific antibodies or naked antibodies for the same target? And if they do, is there some provision where they make your iPSC-derived cell therapy a priority? Just we've seen that in other instances where the CAR-T, as an example, is the leader, and then it's followed very quickly by a bispecific or an ADC, is there anything to protect against that in the collaboration?
Scott Wolchko -- President & Chief Executive Officer
There's nothing to necessarily protect against that in the collaboration. The reverse might be true in this collaboration where they may already have a bispecific which we are creating a CAR NK or CAR-T cell product out of it, using a binding domain that may actually already be in late-stage preclinical or clinically validated.
Jim Birchenough -- Wells Fargo -- Analyst
Just one final one, Scott, on the deal. You mentioned that there's no overlap with anything you're working on internally at Fate. Do they have access, though, to the FT538 master cell bank? Could they make use of that to kind of accelerate the development of the partner assets?
Scott Wolchko -- President & Chief Executive Officer
So to be clear, they don't have access to it, but certainly, we can use it. They -- Janssen, to be clear, is handing us the binding domains, and we are building the CAR constructs. And so I think the direction you're headed in were might we see first-generation product candidates under the collaboration that arise using FT538 as a backbone? Yes, that's a distinct possibility.
Jim Birchenough -- Wells Fargo -- Analyst
Great. Well, thanks for taking the questions. Congrats on all the progress.
Scott Wolchko -- President & Chief Executive Officer
Thank you.
Operator
Your next question comes from Alethia Young with Cantor.
Alethia Young -- Cantor Fitzgerald -- Analyst
Hey, guys. Thanks for taking my question or two and congrats on the progress. One, I was just kind of curious about how you're thinking about clinical trial sites like expanding them. I noticed you referenced maybe some potential additional sites. So I just wonder how much of a strategy will that play? And it also seems like an interesting move long term. And then when you look at the Janssen collaboration, I guess, what's the one piece you think that really is that big secret sauce? Is it the manufacturing capability? Or is it just a natural synergy that you have? Like what do you really think is like the value-add? I'm sure there was a lot of interest and people doing a deal with you guys. Thanks.
Scott Wolchko -- President & Chief Executive Officer
Sure. I would say with respect to clinical sites, yeah, I mean we're going to be aggressive in adding clinical sites. I think one of the unique opportunities that we have, having a potentially outpatient therapy and having product that's available off-the-shelf, is that we can move away from the centers of excellence like, for instance, a Memorial Sloan Kettering or an MD Anderson, which have obviously pioneered CAR-T cell therapy. There's a tremendous amount of competition, obviously, at those centers of excellence with respect to delivering product. I think we have the opportunity to broaden the number of clinical sites that we potentially go to given the off-the-shelf nature of our product candidate.
With respect to the Janssen collaboration, I think there's -- I mean I think there's multiple points of value that we see in our product pipeline and -- we see in our platform and that we hope others also see in this platform. I think one of the differentiating features of what we do, and I sort of just alluded to it with the response to Jim, was this notion that I think folks do believe as we move forward in the next two, three, five years, in order to really address solid tumors, we will have multiplexed engineered functionality embedded into cell therapies. And I think that's very challenging, to do three, four, five edits batch by batch at a cell population level. And so being able to, for instance, engineer a single cell, characterize a single cell with three, four, five edits and use that in a renewable fashion as a starting material, I think just provides some really, really powerful advantages as you think about cell therapy going forward. I think that's one of the really distinguishing features of what we do, being able to collapse all the engineering into literally a onetime event.
Alethia Young -- Cantor Fitzgerald -- Analyst
Great. Thank you very much.
Scott Wolchko -- President & Chief Executive Officer
Sure.
Operator
Your next question comes from Yigal Nochomovitz with Citi.
Carly Kenselaar -- Citi -- Analyst
This is Carly on for Yigal. Thanks very much for taking our question. First question we had was for the FT516 ongoing trial. Can you just give us a sense for where you are in the dose escalation and then what you see as kind of the key learnings from the next data update in the context of your longer-term strategy for this program?
Scott Wolchko -- President & Chief Executive Officer
For FT516? Yeah, for FT516, we're still early in dose escalation when, obviously, the COVID pandemic hit. We're continuing to add sites to the FT516 program. I think FT516, if you look at it, it is the first engineered IPS-derived cell therapy. The CD16 receptor we think is really novel and powerful because we can use it to hit multiple antigen targets. And so getting that first glimpse of using, for instance, FT516 in combination with monoclonal antibody therapy, in this case, Rituxan, I think, is going to be really interesting to us.
I'd also say that the setting for FT516 as a monotherapy is AML. And there's a lot of historical precedent with respect to the use of donor-derived NK cells in the AML setting. And so being able to, for instance, benchmark over time a product candidate like FT516 or FT538 in the setting of AML, I think, could be really interesting and potentially is a really powerful therapeutic given the precedent that exists with respect to NK cells and antileukemic activity in the AML setting.
Carly Kenselaar -- Citi -- Analyst
Got it. That's helpful. And then just building on some of the prior questions around the Janssen deal and potential future partnering opportunities, can you talk about the process and kind of the time lines associated with developing an iPSC-derived product candidate once a partner comes to you with a desired target?
Scott Wolchko -- President & Chief Executive Officer
Yes, I think it depends a little bit. It depends on -- and I've said this before, Fate Therapeutics is not necessarily today an expert in developing -- in identifying and developing the latest and greatest cancer targets or binding domains and optimizing binding domains to access those targets. So it really does depend on, as an example, what the partner might be contributing at day one to the collaboration. So in the case of Janssen, at least some of the antigen targets we've talked about, Janssen is showing up at some level with a validated binding domain that they're excited about.
And so if someone, for instance, were able to hand us a validated binding domain, and we construct -- built a CAR construct and dropped it into, for instance, the FT538 backbone, we potentially could have an IND candidate in 18 months. Let's just pick 18 months as a reasonable time frame. But that depend -- that's really incumbent on a partner having confidence in contributing a validated binding domain around which we could build a CAR NK or a CAR-T cell product.
Carly Kenselaar -- Citi -- Analyst
Great. That's very helpful. Thanks for taking the questions.
Scott Wolchko -- President & Chief Executive Officer
Sure.
Operator
Your next question comes from Daina Graybosch with SVB Leerink.
Daina Graybosch -- SVB Leerink -- Analyst
Hi, thanks for the questions. A couple. The first one is if you could just help us understand when we might see some clinical data for FT596 primarily but also 516, 500 and ProTmune, which I think maybe you had initially thought we'd see data in second half.
Scott Wolchko -- President & Chief Executive Officer
Yes. So with respect to -- I'll take them sort of one at a time. So with ProTmune, I'll start with actually ProTmune. With ProTmune, we -- I think we announced we fully enrolled the ProTmune study in, I want to say, November of 2019. And so ProTmune has two key data sets associated with it. There's a day-100 data set where we're looking at cumulative incidents of Grade 2 through Grade 4 GVHD. And so obviously, our patients have fully progressed through that day-100 end point. And then there's this key secondary end point. And the key secondary end point really captures the totality of the hematopoietic stem cell transplant outcome. And so for instance, it's a composite end point of moderate-to-severe chronic GVHD, relapse and survival. So an end point that's commonly referred to as GRFS. And that's a day-365 readout. The study will be blinded, is currently blinded and will stay blinded throughout the assessment of both day 100 and day 365. So if you think about like when we will hit day 365, we likely will not have ProTmune data until the first half of 2021, if I did all that math correctly.
With respect to the IPS-derived programs, FT500, FT516, FT596, we're not going to go patient-by-patient with respect to data, so we will not do that. We will wait until we have essentially an informative group of patients through dose escalation and then provide that type of data. Obviously, we have been delayed, and we think there's going to be some delays with respect to new site initiation and patient enrollment, new patient enrollment, because of the COVID pandemic. And so we will provide more transparency as we approach the enrollment and the disclosure dates for the clinical data.
Daina Graybosch -- SVB Leerink -- Analyst
Awesome. And then my second question on the whole -- on the completely different end. For this new pan-tumor MIC AB target, I don't think you mentioned whether it's a CAR NK or CAR-T. I wonder if you can speak to that. And how close is it to the Celyad CAR-T program and maybe what you've learned from that program as you take yours into the clinic?
Scott Wolchko -- President & Chief Executive Officer
Sure. I'll touch this at a high level because we're about to disclose this at ASGCT. So at ASGCT, you will see data, both with respect to CAR MICA, MICB in both NK cells and T cells. So you'll see some initial data in both as it relates to CAR MICA and MICB.
With respect to other types of programs, I would say we've obviously looked a lot at NKG2D with -- and its ability, given it's a sort of a key activating receptor on NK cells. The targets of NKG2D commonly, like MICA, MICB, can shed. And so that is one I think that is -- I think that one of the significant differentiation -- differentiating features of this program is we're all very familiar of mechanisms associated with T cell escape. I think there's more and more data now emerging that NK cell tumor escape also exists. And this is potentially one of the prominent mechanisms. The shedding of stress ligands on tumor cells is potentially a very prominent mechanism of tumor escape, especially in solid tumors. And that's what we were really intrigued about with respect to this program because we think this program in targeting MICA, MICB, and we'll get into it with the alpha-3 domain, specifically of the ligand, we can overcome the shedding and NK cell escape.
Daina Graybosch -- SVB Leerink -- Analyst
That's very helpful. Thank you.
Scott Wolchko -- President & Chief Executive Officer
Sure.
Operator
Your next question comes from David Nierengarten with Wedbush Securities.
David Nierengarten -- Wedbush Securities -- Analyst
Hey, thanks for taking the question. I just had a quick one on thinking about the autologous transplant setting in NK596 -- or 596 program. This has been a goal for quite some time to prevent relapses in transplants. And I was just wondering how you were thinking about the end points and disposition of patients or, just generally, if you could provide any more detail on that study at Minnesota? Thanks.
Scott Wolchko -- President & Chief Executive Officer
Sure. Wayne, do you want to take that?
Yu-Waye Chu -- Senior Vice President, Clinical Development
Yes. So as you mentioned, prevention of relapse in the autologous stem cell transplant setting for patients with aggressive lymphoma still remains an unmet medical need. And so with respect to the specific study, I think a few things to point out. First, the patient population that's selected are patients with known high risk of disease that are defined both by biologic characteristics as well as their response to initial immunochemotherapy. So patients who've had relatively poor responses to things like RCHOP, and then come on and receive salvage immunochemotherapy followed by stem cell transplant. That's the eligible population for this. And so this population was picked in large part because the survival outcomes for these patients, even when they are able to get to the transplant situation, are relatively poor with relatively short event-free survival and progression-free survival. And so the purpose of this study is to see whether or not the addition of FT596 in the post-autologous stem cell transplant setting results in prolonged progression-free survival and event-free survival, which are among the important end points of this study.
David Nierengarten -- Wedbush Securities -- Analyst
And I mean is 18 patients the right number to -- sorry, for a quick follow-up, the right number to see that when you stratify by risk factors? Or are these patients because they're -- maybe they didn't get completely -- they didn't experience a complete response or a partial response, so they -- what's the frequency of relapse in the next six or 12 months? Or basically, how quickly could we see a potential divergence in outcomes with patients treated with 596?
Yu-Waye Chu -- Senior Vice President, Clinical Development
Yeah. So good questions. But I think it's also worth remembering that one of the primary end points of the study is also to understand the safety and tolerability of FT596 in the post-transplant setting. And so the 18 patients is admittedly a small number, but it's really, in large part, to characterize the safety and tolerability. And it really depends on how the clinical tolerability is with the first set of patients that if there's any compelling evidence of activity, then we would definitely expand -- consider expanding the number of patients in order to get to a number of patients that allow us to more robustly determine whether or not the outcomes are better than current standard of care. And I think in that regard, particularly in patients who don't achieve a deep response with initial immunochemotherapy, outcomes for these patients, even when they get to transplant, you're talking about event-free survival measured is less than a year and progression-free survival is similarly less than a year. So if you treat patients on the study and you find that a fair proportion of these are having event-free survival in excess of that, then there will be opportunities to expand the study to get a more precise read on that.
David Nierengarten -- Wedbush Securities -- Analyst
Got it. All right. Thank you.
Operator
Our next question comes from Biren Amin with Jefferies.
Biren Amin -- Jefferies -- Analyst
Hi, guys. Thanks for taking my questions. Maybe on 500 -- FT500. You've announced that you've dosed three patients with 300 million cells in combination with checkpoints. Can you just talk about how many cell doses the patients received? And I guess can you maybe talk about the background of the patient in terms of tumor type? In particular, did you have any patients with non-small cell lung cancer which led you to expand into that setting?
Scott Wolchko -- President & Chief Executive Officer
Yeah. So this is Scott. So these were the last three patients in the dose escalation phase of the study that we had treated. All three patients were eligible to receive the second cycle. And you should assume some of the patients, at least some of the patients received all 6 doses. So the hypothesis, as you know, the Phase I study, whether it be monotherapy or checkpoint inhibitor combination, the hypothesis of the study really initially was a basket study to look at safety and look at the tolerability of initial dose. We certainly did not enrich for non-small cell lung cancer patients in the allcomers dose escalation phase.
With respect to expansion, this is where we're taking a biological bet, if you will. We think it is well informed based on the literature that's out there with respect to -- and there's a significant body of literature out there with respect to checkpoint inhibitor in non-small cell lung cancer and, for instance, the mutations, that lead to down-regulation in MHC Class 1, which is where we think NK cells might have a very unique advantage in attacking those types of tumors. So I would say the hypothesis in going after non-small cell lung cancer is not necessarily driven by the clinical data that we observed in dose escalation but more based on what we've been able to glean, including talking to KOLs in the checkpoint inhibitor space around non-small cell lung cancer as it's practiced today with checkpoint inhibitor.
Biren Amin -- Jefferies -- Analyst
And Scott, for the non-small cell cancer -- lung cancer study, what type of IL-2 support will patients be required to have? Can you just maybe provide additional color on that as well as are you enrolling patients with certain PD-L1 baseline, TMB or CD3 counts?
Scott Wolchko -- President & Chief Executive Officer
Yeah. And so we are not -- today, we are not necessarily prospectively selecting on MHC Class 1 level, we are doing pretreatment tumor biopsy. So that is mandatory to get a pre-treatment biopsy, must have that. And so we will absolutely be able to classify MHC Class 1 expression levels as we enroll patients. We will have that information. And so that will be helpful to us. With respect to IL-2 support, we're excited about adding IL-2 because we think that's important in order to activate -- properly activate the NK cells to the best of their ability. And we will be giving a -- it's a subtherapeutic dose, but we give a subtherapeutic dose essentially with each dose of FT500.
Biren Amin -- Jefferies -- Analyst
Okay, great. Thank you.
Scott Wolchko -- President & Chief Executive Officer
Sure.
Operator
Your next question comes from Mara Goldstein with Mizuho.
Mara Goldstein -- Mizuho -- Analyst
Hi, can you hear me?
Scott Wolchko -- President & Chief Executive Officer
Yes.
Mara Goldstein -- Mizuho -- Analyst
Thank you. So I wanted to ask two questions. One, with respect to MICA and MICB, sorry, MICA/B. They're not the only stress ligand. So I'm just wondering if there is -- if the -- if you're able to sort of quantify what the losses in tumors and relative to what would necessarily be normal and compared to sort of the broader group of stress ligands that are affected from this process. And so I'm curious about that from that perspective. And then just on the CAR BCMA, I'm just wondering what you can point us to from at least a preclinical perspective that can show us differentiation between sort of where you're going with yours, where -- versus where the field is right now.
Scott Wolchko -- President & Chief Executive Officer
Sure. With respect to CAR BCMA, I'd sort of ask you to hold your question for about two days because the FT576 poster is going to be presented at ASGCT as well, I think, on Wednesday or Thursday of this week. And so you will see sort of -- some of the differentiating features of FT576, which again, includes, and we are big believers in this, the ability to attack multiple antigens at the same time. And so we think that's one of the unique advantages with the product candidate, not that it's just off-the-shelf but we will be able to do multi-antigen targeting, for instance, in combination with an anti-CD38 mAb, as an example, not just the CAR BCMA. And so we're excited about that.
With respect to MICA, MICB, I mean it's early. Totally agree that there are multiple stress ligands that can be expressed by tumor cells. And obviously, NK cells can interact with those types of stress ligands. It's one of the reasons we're excited about NK cells is because NK cells have a sort of an array of activating receptors that can interact with these stress ligands. I would say if you look at certain solid tumors, and I'm happy to send you some papers on this, MICA, MICB as a ligand is predominantly expressed on certain solid tumors as the stress ligand. And so we think it is a very significant target for which to go after. It is a target, as we mentioned, that is absolutely subject to shedding, though. And I think it's one of the challenges that's emerging in the setting of solid tumors is that these tumors are very smart and crafty. And they have mechanisms to escape T cell recognition as well as NK cell recognition. And so targeting these stress ligands in a way where you can access the solid tumor, engage the solid tumor and overcome these escape mechanisms is something we're super excited about.
Mara Goldstein -- Mizuho -- Analyst
All right. Thanks. I appreciate it.
Operator
The next question comes from the line of Ben Burnett with Stifel.
Ben Burnett -- Stifel -- Analyst
Good afternoon. Thanks so much for taking my question.
Scott Wolchko -- President & Chief Executive Officer
Sure.
Ben Burnett -- Stifel -- Analyst
I guess, first, can you just talk about the 516 study for COVID-19? Specifically, what exactly are states role here? I'm just curious if you can talk to the researchers that you'd be responsible for that program. And then just as a quick follow-up, how does this impact 516 inventories as it relates to the Company-sponsored trials? Thanks so much.
Scott Wolchko -- President & Chief Executive Officer
Sure. So I -- your second part of your question first. I mean, it's not a significant drain on our inventory with respect to the inventory we have on hand with respect to FT516. You should assume that we've done more than one manufacturing run for FT516, and we have hundreds of doses that are, in fact, available. With respect to how this all came about, we did -- we actually did not initiate the discussions here. The infectious disease team at the University of Minnesota approached us, wanted to know if we'd be willing to supply FT516 to support a UMN-sponsored study. Obviously, the University of Minnesota has been a terrific partner of Fate Therapeutics for years. And so we were happy to agree to supply product to them. And if we can provide another tool in the arsenal to try and fight COVID-19, we're more than happy to do that.
I think there is actually some strong rationale potentially for using NK cells, obviously, to fight infectious disease. I think one of the things that was appealing to us as we looked at the clinical design that the University of -- the folks, the infectious disease team, at the University of Minnesota was putting forth, is again continuing to reinforce this idea of being able to give patients multiple doses.
So patients in the study are actually receiving multiple doses over a week. And it's actually a very interesting study from a clinical translation learnings perspective for us that may benefit us actually on our oncology programs because the intra-patient dose escalation starts at 90 million cells, goes to 300 million cells, goes to 900 million cells, all in the course of a week. So there's administration of day one, day four, day seven, where you go very quickly from 90 million to 100 million cells all the way to 900 million cells. And so we will be able to -- from a clinical translation perspective, we'll be able to get an interesting read on what is a very high dose level in a relatively short period of time.
Ben Burnett -- Stifel -- Analyst
Okay. That's great. That's great context. And maybe just a quick follow-up to sort of the Janssen collaboration discussions that we've had. I guess I just wanted to ask about your appetite specifically for maintaining ownership of your current clinical candidates. I guess is there a scenario where they could be on the table, too?
Scott Wolchko -- President & Chief Executive Officer
Yeah. I mean I'm not going to rule anything out. I mean anything is a possibility. I think we think that we, both with respect to, for instance, let's just pick 596 as well as 576, obviously, there -- if you think of CD19 and if you think of BCMA, these are targets, specifically in the CAR-T cell world, that has been largely derisked. And we do think we have a very disruptive approach to going after the CD19 as well as the BCMA market with an off-the-shelf paradigm. And so as we look at it today, and again, the world can change, but as we look at today, we're more than prepared to go after and pursue those opportunities on our own.
Ben Burnett -- Stifel -- Analyst
Okay. That's fantastic. Thanks so much.
Scott Wolchko -- President & Chief Executive Officer
Sure.
Operator
Your next question comes from Matthew Biegler with Oppenheimer.
Kalpit Patel -- Oppenheimer -- Analyst
This is Kalpit on for Matt, and thanks for taking our questions. First, for the relapse prevention program for 596, are the investigators planning to include patients who received prior CAR-T therapies? Or is it just going to be prior chemo-treated patients?
Scott Wolchko -- President & Chief Executive Officer
It's most likely prior chemo only. And so these patients are, for instance, they will have to have failed only one line of therapy, are eligible for autologous hematopoietic stem cell transplant and are at high-risk for relapse. So they may have only, for instance, received one line, have qualified for transplant but are deemed at high-risk for relapse. And I think Wayne touched on it. The rate of relapse in these high-risk patients is high, and they do relapse quickly. And so most likely, these patients will have -- will not have received CAR-T cell therapy.
Kalpit Patel -- Oppenheimer -- Analyst
Okay. And then switching to 516 for solid tumors, specifically the combo with avelumab, are you planning to restrict enrollment based on patient PDL-1 expression levels?
Scott Wolchko -- President & Chief Executive Officer
We probably will not do that initially as part of a dose escalation. And the first part of it -- I know we're going to drive to demonstrate safety and tolerability of FT516 in combination with avelumab. But certainly, yes, getting pre-treatment biopsies is something that we're big believers in and investing a significant amount of our dollars and understanding in these clinical studies in the clinical translation aspect of it. So all that kind of information is super helpful and informative. But in the dose escalation, we're not necessarily going to restrict that.
Kalpit Patel -- Oppenheimer -- Analyst
Okay. All right. Thank you very much.
Scott Wolchko -- President & Chief Executive Officer
Sure.
Operator
Next up is Michael Schmidt with Guggenheim.
Michael Schmidt -- Guggenheim Partners -- Analyst
Hey, guys, thanks for taking my questions. I had one on FT819, the CAR-T program. Obviously, it's early -- earlier than some of the other programs that were talked about. But with the IND filing coming up here in the second quarter, I was just wondering how you think about things like optimizing the -- or looking at the preconditioning or the persistence window in this early Phase 1 study on one hand and also maybe how you think about read-through from other allogeneic CD19 CAR-T programs, such as, for example, the donor-derived programs where we see some data at ASCO coming up.
Scott Wolchko -- President & Chief Executive Officer
Yeah. I think it's -- I mean I'm super interested in seeing what comes out of, for instance, the other donor-derived CAR-T cell programs. I think it's going to be really fascinating to understand and get a first look at this -- at the clinical data. I think there's certainly things that we can learn from those studies. I also think there's enough diversity in the different programs where a total read through, I think, is a bit difficult.
I mean I think you've heard me say in the past, and this comes from firsthand experience at Fate Therapeutics, we don't believe donor-derived cell therapy is the same as IPS-derived cell therapy. There's a lot of heterogeneity still that exists between donors. And then there's a lot of heterogeneity exists with respect to engineering. And so I think there can be some very interesting learnings. But at the same time, I don't view it as a direct read through given the variances that do exist between, for instance, donors and even engineering strategies and approaches. So I mean I think I'd leave it at that, but we are really interested in getting a look at the first data from the other folks.
I think one of the things that we are a believer in of is that we like the idea of being able to give multiple doses. I think that is important, being able to give multiple doses, because I think that has the potential to essentially, in some respect, to drive persistence by creating the right PK/PD window through a multi-dosing strategy.
Michael Schmidt -- Guggenheim Partners -- Analyst
And I guess philosophically, and maybe that goes into that, but how do you think about a window of persistence maybe to avoid host-versus-graft rejection? I think there's a few different things that are being tested by competitors, B2M knockout, more preconditioning, less preconditioning, longer preconditioning or none at all. I guess what's -- philosophically, where do you stand? And how do you -- how will you approach this in your Phase 1 study?
Scott Wolchko -- President & Chief Executive Officer
Sure. I think there's a lot to be learned. I think you -- the community generally can jump to some conclusions that may not necessarily be true north as an example. And I'm not suggesting NK cells are the same as T cells, another thing that we have to learn. But we went into the FT500 study with very light lympho-conditioning, keep that in mind, light lympho-conditioning, and we successfully demonstrated that you could give up to six doses over a 45-day period without seeing a B-cell or T cell-mediated immune rejection program emerge. So I think we have to look and see what data emerges, follow the data. I'm optimistic, quite honestly, given what I've seen from FT500, the FT500 program, that you can, in fact, give multiple doses over a 45-day period without seeing significant T cell-mediated immune rejection programs. And keep in mind, we gave a single lympho-conditioning dose on day minus four and day minus three and then treated the patients for the next 45 days. So I think there's a lot to learn in the field.
I think as it relates to what type of window you ultimately need, I think there's data emerging, and there's different avenues to think about this. But I do go back to at least the autologous CAR-T cell field, and let's use that as a baseline, really having a profound antitumor effect during the first 20 to 30 days appears to be key. So that first 30-day window, I think, appears to be a really important window to drive sort of profound and durable antitumor activity. Now interestingly enough, I'm not suggesting one dose is necessarily the best strategy to give during that 30-day period. I think you may want to come in with multiple doses during that 30-day period to drive the best responses.
Michael Schmidt -- Guggenheim Partners -- Analyst
Okay. Great. Thanks for the thoughts, Scott. I appreciate it.
Scott Wolchko -- President & Chief Executive Officer
I mean the one thing I'd add on that, like, just to follow up, right, you can lympho-deplete a patient, and you can create a 30-day window and you could have a persisting cell. It doesn't mean that cell has the same killing potential at day 14 as it did at day 0. And I think we're learning a lot about that. That cells that exist in the body even for two weeks, three weeks don't necessarily have the same killing potential as they did at day 1. And so I think it goes well beyond just creating the right window for antitumor activity. You have to have potent cells, and I think you're going to have to give multiple doses of potent cells.
Operator
And our last question comes from the line of Peter Lawson with Barclays.
Peter Lawson -- Barclays -- Analyst
Thanks, Scott. Thanks for taking the questions. So just as we kind of think about the trials you've got started and starting and there's a lot of options around the platform itself, and what indication of construct do you think you could get to a pivotal trial fastest?
Scott Wolchko -- President & Chief Executive Officer
I think FT596 is a product candidate that is positioned to quickly get into. Now we have to show safety, right, and we have to show sort of efficacy. But I think it is a product candidate that we can look at. CD19 is a derisked target. We do think we have a highly differentiated strategy in it being off-the-shelf, in being able to potentially give multiple doses and potentially going after multiple tumor-associated antigens. So I look at FT596 as the target's derisked, and I think we have a very differentiated product in that setting.
With FT500, I think we're learning a lot. But I think, ultimately, to go after solid tumors, I've talked about this on this call, you're going to have a multiple -- probably multiple different engineered elements associated with that product to truly drive durable responses. And so I think when we look at where we're going, we're assuming that, as we go forward and take products deeper and deeper into registration studies, they're most likely multiplexed edited cell therapies.
Peter Lawson -- Barclays -- Analyst
Great. Thank you. And then on your comment just around -- I mean you're using these in an outpatient setting. What percentage of your trial sites are outside areas of excellence, the idea that you can move outside those areas of excellence? And -- yeah, thanks.
Scott Wolchko -- President & Chief Executive Officer
I mean we initially started there. And so I think our clinical trial sites are publicly available on clinicaltrials.gov. I mean not surprisingly, we initially started at some of these centers of excellence, but some of the folks that we're working with now are -- and getting activated remotely are outside of what you would consider sort of the top center of excellence like a Memorial Sloan Kettering or an MD Anderson. For instance -- I'm not suggesting sort of San Diego isn't a hot bed of cancer research, but we work with Moores Cancer Center at UCSD, which is right across the street. So that's certainly more community-based than, for instance, MD Anderson.
Peter Lawson -- Barclays -- Analyst
Great. Thank you. And then on the expansion in non-small cell lung cancer, the FT500, when can we see data? And then how should we think about, I guess, teasing out any effects that IL-2 or PD-L1 potentially adds?
Scott Wolchko -- President & Chief Executive Officer
Yeah. I think with respect to IL-2, we're certainly giving subtherapeutic doses of IL-2. That's not uncommon. If you think about what we've seen in other programs like TIL therapy. TIL therapy gives subtherapeutic doses of IL-2. I think with respect to the PD-L1 contribution and checkpoint inhibitor, I mean these patients that have progressed or failed checkpoint inhibitor therapy were given the exact inhibitor that they just progressed or failed on. That said, I think there is -- and people have certainly demonstrated, gosh, you can resensitize a patient giving a checkpoint inhibitor. But again, I think some of what we'll be able to tease out is what do the response rates look like relative to checkpoint inhibitor alone in patients that have already failed checkpoint inhibitor therapy.
Peter Lawson -- Barclays -- Analyst
Great. Thanks so much. Thanks for taking the questions.
Scott Wolchko -- President & Chief Executive Officer
Sure.
Operator
I am showing no further questions at this time. I would now like to turn the conference back to Mr. Scott Wolchko.
Scott Wolchko -- President & Chief Executive Officer
Thank you.
Operator
You're welcome.
Scott Wolchko -- President & Chief Executive Officer
Thank you, everyone, for participating in today's call. We look forward to talking to you in the near future. Be well.
Operator
[Operator Closing Remarks]
Duration: 77 minutes
Call participants:
Scott Wolchko -- President & Chief Executive Officer
Yu-Waye Chu -- Senior Vice President, Clinical Development
Ted Tenthoff -- Piper Sandler -- Analyst
Robyn Karnauskas -- SunTrust Robinson -- Analyst
Jim Birchenough -- Wells Fargo -- Analyst
Alethia Young -- Cantor Fitzgerald -- Analyst
Carly Kenselaar -- Citi -- Analyst
Daina Graybosch -- SVB Leerink -- Analyst
David Nierengarten -- Wedbush Securities -- Analyst
Biren Amin -- Jefferies -- Analyst
Mara Goldstein -- Mizuho -- Analyst
Ben Burnett -- Stifel -- Analyst
Kalpit Patel -- Oppenheimer -- Analyst
Michael Schmidt -- Guggenheim Partners -- Analyst
Peter Lawson -- Barclays -- Analyst
